The purpose of this study was to assess the effect of the multidrug resistance modulator cyclosporine (CsA) on the pharmacokinetics of etoposide and mitoxantrone in children with de novo acute myeloid leukemia (AML). Serial blood samples for pharmacokinetic studies were obtained in 38 children over a 24-h period following cytotoxin treatment with or without CsA on days 1 and 4. Drug concentrations were quantitated using validated HPLC methods, and pharmacokinetic parameters were determined using compartmental modeling with an iterative two-stage approach, implemented on ADAPT II software. Etoposide displayed a greater degree of interindividual variability in clearance and systemic exposure than mitoxantrone. With CsA treatment, etoposide and mitoxantrone mean clearance declined by 71% and 42%, respectively. These effects on clearance, in combination with the empiric 40% dose reduction for either cytotoxin, resulted in a 47% and 12% increases in the mean AUC for etoposide and mitoxantrone, respectively. There were no differences in the rates of stomatitis or infection between the two groups. CsA treatment resulted in an increased incidence of hyperbilrubinemia, which rapidly reversed upon conclusion of drug therapy. The variability observed in clearance, combined with the empiric 40% dose reduction of the cytotoxins, resulted in statistically similar systemic exposure and similar toxicity. Leukemia (2002) 16, 920-927.
Introduction
P-glycoprotein (P-gp), encoded by the MDR1 gene, is an ATPase-dependent multidrug transporter potentially responsible for multidrug resistance (MDR) in many tumors. It is a target for modulation by pharmacological inhibitors since its expression can be increased at diagnosis or after chemotherapy. 1, 2 Its expression confers a poor prognosis in adults with acute myeloid leukemia (AML), particularly in the elderly. [3] [4] [5] P-gp expression has been detected in children with AML and less commonly in children with acute lymphoblastic leukemia (ALL). 6, 7 Many childhood solid tumors including neuroblastoma, rhabdomyosarcoma, undifferentiated sarcomas, osteosarcoma, Ewing sarcoma, and retinoblastoma also express P-gp. 8 Studies of the prognostic significance of P-gp expression in pediatric cancers remain controversial. [9] [10] [11] [12] Some show that its expression might be related to poor survival or risk of relapse, whereas others show no prognostic significance. [13] [14] [15] [16] [17] [18] [19] [20] Studies using cyclosporins to modulate MDR [21] [22] [23] [24] [25] have been performed in children with AML or retinoblastoma. Recently, phase II trials of P-gp reversal with cyclosporins have shown improved remission rates in adults with relapsed and refractory AML. 26, 27 A follow-up phase III trial that randomized CsA without adjustment of daunorubicin dosing showed increased drug concentrations and prolonged survival in patients who received the modulator. 28 The design of clinical trials of MDR1 modulation has been complicated by potential for drug interactions. For a number of cytotoxins, such as etoposide, doxorubicin, paclitaxel, and others, drug clearance has been shown to be decreased by the modulators, presumably through effects on excretion and/or metabolism. 2 Thus, to best test the hypothesis that MDR1 modulation confers clinical benefit, it is critical to adjust the dose of cytotoxin in order to provide similar blood concentrations, thus removing dose intensification as a confounding variable.
In this trial, children with de novo acute myeloid leukemia (AML) were randomized to receive or not receive CsA in combination with etoposide and mitoxantrone during consolidation therapy. The doses of cytotoxins were empirically reduced 40% in the CsA group in an attempt to achieve comparable systemic drug exposure to the control group. The purpose of this study was to evaluate the effect of CsA on the pharmacokinetics of etoposide and mitoxantrone and to validate that our empiric dose adjustment provided similar systemic drug exposure between the two groups.
Patients and methods

Patient eligibility and treatment protocol
Patients with newly diagnosed AML who gave informed consent were enrolled on Pediatric Oncology Group (POG) Study No. 9421. Patients were excluded with the French-AmericanBritish (FAB) subtype M3, therapy-related AML (tAML), and preexisting Fanconi aplastic anemia. All patients treated at POG phase I institutions were eligible for pharmacokinetic studies.
Patients were randomized to one of two induction regimens: (1) 
Sample collection
On days 1 and 4 of etoposide and mitoxantrone treatment, blood samples were collected in heparinized glass tubes before etoposide and mitoxantrone infusion, followed by sampling at 5 and 20 min, and 1, 3, 6, 12 and 24 h after mitoxantrone infusion. These coincided with 1.6, 1.9, 2.5, 4.5, 7.5, 13.5, and 25.5 h after etoposide infusion. Additional blood samples were obtained at 36 and 48 h after day 4 doses. After centrifugation, plasma was separated and divided into a polypropylene tube with 0.3 ml of 5% ascorbate for mitoxantrone analysis and in a polypropylene tube for etoposide analysis. Samples were stored at −80°C, batched, and sent for analysis to the Stanford University School of Medicine General Clinical Research Center pharmacokinetics laboratory.
CsA assay
CsA levels were analyzed in the clinical laboratories at participating institutions. Concentrations were measured using nonspecific fluorescence-polarization immunoassay (TDx; Abbott Laboratories, North Chicago, IL, USA) with a sensitivity of 40 ng/ml and an interassay coefficient of variation of less than 10%. 29 
Etoposide assay
Total plasma etoposide was analyzed by reverse-phase HPLC using a zinc precipitation method and teniposide as an internal standard gas previously described. 30 HPLC assays for etoposide were performed using a Waters 717 autosampler, a Waters column oven, a Waters 510 pump, a Waters 996 Photodiode array detector, and a Millenium 2000 data manager (Water and Associates, Milford, MA, USA). Etoposide and its internal standard, teniposide, were detected at 230 nm. In this procedure, for calibration standards and patient samples, 280 l of plasma was vortexed with 20 l of 40% zinc sulfate solution and the internal standard in a microcentrifuge tube, and allowed to precipitate at 0°C overnight. Samples were then microcentrifuged at 13 000 r.p.m. for 5 min, allowed to stand at room temperature for 2 h, and again microcentrifuged. Next, 100 l of supernatant was injected on to a Bondapak C18 phenyl column (10 mm × 3.9 mm × 300 mm; Leukemia Waters and Associates) at 32°C, with a mobile phase consisting of 35% acetonitrile, 64% water, and 1% acetic acid, at a flow rate of 1.5 ml/min. Retention times for etoposide and teniposide were 5.1 and 12.5 min, respectively. The lower limit of quantitation was 0.25 g/ml and the interday and intraday coefficients of variation were Ͻ7.5%.
Mitoxantrone assay
Total plasma mitoxantrone was analyzed by reverse-phase HPLC with slight modifications to methods reported 31,32 using ametantrone (a gift provided by Wyeth-Ayerst Research, Philadelphia, PA, USA) as an internal standard. Mitoxantrone and ametantrone were detected at 610 nm. In this procedure, 500 l of plasma with the internal standard were added to a final concentration of 50 ng/ml and passed through a C18 BondElut solid-phase extraction column that was preconditioned with 3 ml of methanol followed by 3 ml of HPLC-grade water. Next, the analytes were eluted from the column (with 400 l of 0.1 n methanolic HCL) and 100 l was injected on to a Bondapak C18 phenyl column (10 mm × 3.9 mm × 300 mm; Waters and Associates) at 25°C, with a mobile phase consisting of 21% acetonitrile and 79% sodium phosphate buffer (pH 2.3 with 0.1% TEA), at a flow rate of 1.0 ml/min. Retention times for mitoxantrone and ametantrone were 5 and 7 min, respectively. The lower limit of quantitation was 1 ng/ml and the interday and intraday coefficients of variation were Ͻ9%.
Mitoxantrone analyses were performed using a Hewlett Packard/Agilent (Palo Alto, CA, USA) HP1100 system, equipped with a G1322A degasser, G1311A pump, G1329A/G1330 autosampler, G1316A column compartment, and a G1315A diode array detector. Chemstation software (v 08.03) controlled all modules and was used for storage, analysis and reporting of chromatography. Software was run in a Windows NT environment on a Hewlett Packard Kayak XA workstation (Palo Alto, CA, USA).
Pharmacokinetics analysis
Patient concentration time point data sets used in the pharmacokinetic analysis included those where samples were collected during a complete 24-h time period following a dose. The pharmacokinetic parameters for etoposide and mitoxantrone were determined using compartmental methods with an iterative two-stage approach implemented on the ADAPT II pharmacokinetic software package (Biomedical Simulations Resource, Los Angeles, CA, USA). 33, 34 For etoposide, a linear two-compartment model was used with the i.v. infusion modeled as a zero order rate input. System parameters estimated included: K 10 the elimination rate constant, V 1 the volume of distribution of the central compartment, K 12 the rate constant from the central to peripheral compartment, and K 21 the rate constant from the peripheral to the central compartment. Secondary (calculated) parameters included: total clearance (CLt), the elimination rate constants for each phase (␣ and ␤), and their respective half-lives. In these calculations CLt = K10 * Vc, CLd = K12 * Vc, T . ␣ = 0.693/␣, and T . ␤ = 0.693/␤. AUC was calculated using the equation: AUC = Dose/CLt.
For mitoxantrone a linear three-compartment model was used with the i.v. infusion modeled as a zero order rate input. System parameters estimated included: K 10 the overall elimin-Leukemia ation rate constant, V 1 the central compartment volume of distribution, and the intercompartmental rate constants: K 12 , K 13 , K 21 and K 31 . In this model secondary (calculated) parameters included: total clearance (CLt), elimination rate constants for each of the elimination phases (␣, ␤, ␥), and their respective half-lives. In these calculations CLt = K10 * Vc and T . (␣, ␤ or ␥) = 0.693/(␣, ␤ or ␥). AUC was calculated using the equation AUC = Dose/CLt. Use of these structural models is well documented for etoposide in children [35] [36] [37] [38] [39] and mitoxantrone in adults. 40, 41 Since the ratio of concentration time points per individual to parameters estimated by the regression models was limited for etoposide and mitoxantrone, parameter estimates were refined using an iterative two-stage Bayesian estimation approach in which initial mean values and variances for each parameter were calculated and used as prior information for each subsequent Bayesian estimation. 42 The analysis was repeated in the following manner: estimates from the first Bayesian estimation were used for the second Bayesian estimation, and so forth, with the prior Bayesian estimates and variances for each cycle updated. That process was repeated until the mean estimate for all parameters and subsequent fit differed by less than 10% of the previous mean estimate. The 10% value was our arbitrarily predefined stopping point.
Initial Bayesian population parameter estimates
Sampling times for etoposide did not allow for full characterization of the concentration time profile near the peak. Therefore, starting parameter estimates were selected from available literature 35, 38, 39 that most paralleled our initial estimates of terminal elimination rate constants of our etoposide-alone patients, using linear regression. The mean initial values and their coefficient of variation (%) used for modeling were: K 10 0.396 h −1 (38%), V 1 3.8 l/m 2 (31%), K 12 0.636 h −1 (122%), and K 21 0.696 h −1 (104%). 38 For mitoxantrone, initial population prior parameter means and variances were calculated using weighted-least-square regression in 12 patients who received mitoxantrone alone (no CsA) and in whom complete concentration time profiles of planned sampling were accomplished over the 24-h period. The mean initial values and their coefficients of variation (%) were: K 10 
Toxicity grading
Toxicity was graded using the common toxicity criteria of the National Cancer Institute. Patients were closely monitored for hyperbilirubinemia and changes in serum creatinine during CsA and chemotherapy infusion. Blood counts were monitored after each cycle of therapy. Incidents of mucositis and infectious complications were also monitored closely and graded accordingly.
Statistical analysis
PK and patient clinical data were tested for normal distribution using the Wilk-Shapiro statistic, 43,44 which indicated most data were not distributed normally (data not shown). Differences in PK parameter estimates for etoposide or mitoxantrone between groups who did and did not receive CsA were compared using Mann-Whitney U test. Comparisons of incidence of toxicities by treatment group used Fishers exact test. The a priori level of significance was P = 0.05 (two-sided). Correlation between AUC and toxicity scores was analyzed using the Spearman rank correlation coefficient.
Results
Patient population
Pharmacokinetic sampling was performed in 38 patients treated at POG phase I institutions. Their ages ranged from 8 months to 17 years. There were 21 males and 17 females, with body weights ranging from 8.4 kg to 134 kg. Twentythree were in the CsA arm and 15 were controls. There were no statistical differences in mean age and weight between the control and CsA-treated groups.
PK analysis: etoposide
Etoposide pharmacokinetics were analyzed in 22 of 23 CsAtreated patients and in 14 of 15 patients in the control arm during the first day of treatment. One patient each in the control group and the CsA-treated group were not included in the analysis due to incomplete sampling (no samples were obtained following the 7.5 h time point). Many sample sets from the 4th day of therapy were incomplete because of noncompliance or difficulties obtaining blood samples for the entire 24-h period, and were not used in the analysis.
Etoposide PK data are summarized in Table 1 . The clearance and AUC of etoposide, with or without CsA showed marked intrapatient variability, as noted by standard deviation values, which in most cases approximated mean parameter values. The addition of CsA to etoposide resulted in a decrease in the mean CLt of 71% (P = 0.031). This effect combined with our empiric 40% dose reduction in etoposide (from 100 mg/m 2 to 60 mg/m 2 ) resulted in a 47% increase in the mean AUC (97 mg*h/l CsA group vs 66 mg*h/l control group, P = 0.119). The percent of the AUC extrapolated for the CsAtreated group was slightly greater than the control group, with mean values of 8.6% and 13.9%, respectively, as a result of the longer terminal T . in the former group. The etoposide T . ␤ increased from a mean (± s.d.) of 3.5 (±1.7) hours in the control group to 6.9 (±3.0) hours, during CsA treatment (P Ͻ 0.001, Table 1 ).
PK analysis: mitoxantrone
Mitoxantrone pharmacokinetics were available for analysis in 22 of 23 patients treated with mitoxantrone and CsA, and 12 of 15 in the control arm during the first day of treatment. In the control group, three patients were not included in the analysis: in one patient no samples were received by the laboratory and in two patients sampling was performed only for the first 12 h. In CsA-treated patients, one patient had sampling performed only during the first 3 h. The majority of sample sets from the 4th day of therapy were incomplete because of noncompliance with the 24-h sampling time period or difficulties in obtaining blood samples, and were not used in the analysis.
Mitoxantrone PK data are summarized in 
PK analysis of CsA
CsA levels were analyzed in clinical laboratories at institutions where patients were treated. Samples were analyzed using a TDx Cyclosporine and Metabolites Serum Assay (TDx; Abbott Laboratories), except for one patient who was monitored using the TDx Cyclosporine Monoclonal Whole Blood Assay (TDxMoAb; Abbott Laboratories). CsA serum concentrations were monitored every 12 h and the dose adjusted to achieve a target concentration between 3000 ng/ml and 5000 ng/ml. Concentrations achieved were in the range of 1180 to 11 198 ng/ml, with a mean (±s.d.) of 3850 (±1663) and a median of 3418 ng/ml.
Toxicity
CsA treatment led to increased incidence of hyperbilirubinemia, with eight of 23 (35%) patients developing grade 3 or 4 toxicity (Ͼ1.5 × upper limit of normal). In all cases hyperbilirubinemia reversed upon discontinuation of CsA. At the time of this analysis, there were 201 patients assessable for toxicity in the entire study population, 104 who did not receive CsA and 97 patients who did. Grade 3-4 hyperbilirubinemia was observed in 42 (43.3%) of CsA-treated patients. This incidence was not different to the rate observed in the entire study popuLeukemia lation (P = 0.49, Fisher exact test). These and other toxicities are shown in Table 2 . There were no differences between groups in rates of stomatitis or infection either within the PK subgroup or when the PK subgroup was compared to the larger study population. Among patients who had PK analysis, there was no correlation between etoposide or mitoxantrone AUC and incidence of hyperbilirubinemia, infection, or stomatitis (Table 3 ). In patients with or without grade III/IV toxicity there was no difference in the mean AUC for etoposide or mitoxantrone (Table  4) . CsA levels in the PK study group did not differ from patients in the larger study population (data not shown).
Discussion
The design of clinical trials of MDR1 modulation has been complicated by potential for drug interactions. Thus, to best test the hypothesis that MDR1 modulation confers a clinical benefit, it is critical to adjust the dose of cytotoxins to provide similar blood concentrations, thus removing dose intensification as a confounding variable. Comparison of PK group vs entire study toxicity, rate of stomatitis in PK group with CsA is greater than control (P = 0.015), all other comparisons are not significant (P Ͼ 0.23). 
Table 4
Comparison of etoposide and mitoxantrone AUCs in patients with and without toxicities?aq1? Table 4 Group Toxicity In this trial in children with AML, mitoxantrone and etoposide were combined with CsA as the P-gp inhibiting agent, during the consolidation phase. As previously reported by Lum et al 45 in adults and Bisogno et al 46 in children, there are significant pharmacokinetic interactions between CsA and etoposide, suggesting that a 50% dose reduction is required to ensure similar systemic exposure. The effects of CsA on the PK of mitoxantrone are, to our knowledge, unknown.
We report the pharmacokinetic analysis in patients from the first randomized study of P-gp modulation in children with de novo AML. Dose adjustment to provide similar drug exposure was a major goal of this study because it allows true comparison of MDR modulation between the randomized groups. In this trial, drug doses of etoposide and mitoxantrone were empirically reduced 40% in the CsA group to achieve comparable drug exposure between the control and the CsA-treated arms. To validate that our empiric dose adjustment provided similar systemic drug exposure between the two groups, we performed a pharmacokinetic analysis of etoposide and mitoxantrone. To our knowledge, this is in addition the first study of the PK of mitoxantrone in children and the effect of CsA on its PK.
The addition of CsA to etoposide or mitoxantrone resulted in marked reductions in clearance of either cytotoxin ( Figure  1) . The clearance and AUC of etoposide, with or without CsA showed marked intrapatient variability, as noted by standard deviation values, in most cases, approximating mean parameter values. Less intrapatient variability was noted for mitoxantrone. When CsA-treated patients were compared to controls, the mean clearance of etoposide and mitoxantrone declined by 71% and 42%, respectively. These effects on clearance, in combination with empiric 40% dose reductions for either cytotoxin, resulted in 47% and 12% increases in the mean AUC for etoposide and mitoxantrone, respectively. However, the large interpatient variability in the pharmacokinetics of either cytotoxin precluded these findings from reaching statistical significance. For example, the 95% confidence interval in the etoposide control group ranged from 26.9 to 105.6 vs 64.4 to 130.7 mg*h/l in the CsA-treated group, suggesting a two-to four-fold variability. For mitoxantrone, the exposure was quite similar, with the 95% confidence interval in the control group ranging from 139.9 to 249.3 vs 167.4 to 274.2 ng*h/l in the CsA-treated group, however again showing approximately 1.5 times variation in exposure.
The differences in etoposide AUC between the control and CsA-treated groups also appear to be slightly overestimated. Using linear dose-clearance relationships, a 40% reduction in dose combined with a 71% decline in CLt would predict for a 30% increase in AUC, rather than our observed 47%. It is possible that this overestimation could be attributable to the Bayesian estimations of V 1 , where no concentration time points were available at the end of the infusion. Another explanation would be differences in the estimation of Ke in the two treatment groups, since etoposide fell below the lower limit of quantitation more rapidly in the control group and less data points were available. However, in all cases, visual inspection of concentration time plots revealed that a minimum of three data points were in the terminal elimination phase of the curve (Figure 1 ). Unfortunately, due to lack of
Figure 1
Simulated concentration time curves for etoposide and mitoxantrone with and without CsA using mean Bayesian population parameter estimates.
sampling of concentration time points at the end of the infusion, alternative methods of analysis, such as noncompartmental approaches to the data, could not be used to resolve these differences.
For mitoxantrone, a 42% reduction in mean clearance was observed in CsA-treated patients when compared to the control group. This effect was adequately compensated for by the 40% empiric dose reduction, as noted by a 12% increase in the mean AUC during CsA treatment.
Rates of stomatitis, infectious complications, and hyperbilirubinemia were similar between the subgroup of patients in the randomized trial undergoing PK analysis and in the general trial population for control and CsA-treated patients ( Table 2 ). In the PK subgroup there was no statistically significant increase in stomatitis or infectious complications. However, the sample size in this PK study would have allowed finding only large differences in toxicity rates. For example, to design a study to detect a difference (increase) in toxicity from 10% to 30%, it would take 72 patients per group (alpha = 0.05, power = 80). Nonetheless, the analysis of the larger trial sample of 211 patients, which included the patients receiving PK analysis, had sufficient power to detect these differences, and no differences in stomatitis or infectious complications were observed. Consistent with these observations, etoposide or mitoxantrone AUC was shown to not correlate with toxicity (Table 3) .
As expected, the incidence of hyperbilirubinemia, an effect attributable to inhibition of bilirubin transport by CsA, was observed. This effect was transient and resolved upon discontinuation of CsA. In the subgroup studied, there was no difference in mean day to neutrophil count recovery between groups with or without CsA (data not shown).
Our findings of the effect of CsA treatment on etoposide pharmacokinetics are similar to those previously reported for adults and children. Lum et al 45 first reported a PK interaction between etoposide and CsA in adults, where a 46% decrease in clearance 45 was observed during CsA treatment. Bisogno et al 46 later reported that CsA altered etoposide PK in children, causing nearly a doubling of AUC, suggesting a 50% decrease in dose to ensure equal exposure. At the time of the design of this study, the data from Bisogno et al 46 were not available, and given an anticipated faster drug clearance in children vs adults, we had selected a 40% dose reduction.
To our knowledge, our study is the first to report the PK of mitoxantrone in children, as well as the effect of CsA on the behavior of this cytotoxin. Despite a prolongation in the terminal half-life during CsA treatment, there was no evidence that it enhanced toxicity to this agent (Tables 1-3) .
P-glycoprotein (P-gp), encoded by the MDR1 gene, is one of the best-characterized forms of clinical drug resistance. It is a target for modulation by pharmacological inhibitors since its expression can be increased at diagnosis or after chemotherapy.
1,2 It has been hypothesized that inhibitors of MDR1 function may improve the efficacy of chemotherapeutic agents, which are substrates of this pump. Since P-gp expression has been detected in children with AML and less commonly in children with acute lymphoblastic leukemia (ALL), 6 ,7 reversal of P-gp function may provide clinical benefit in this disease.
POG 9421 was open to children with de novo AML to test if P-gp blockade by CsA during consolidation therapy increased survival. P-gp is expressed in 10-20% of children with de novo AML, and increased frequency in children with relapsed AML, 12, 16, 19 suggesting that P-gp may be an important factor in chemotherapy resistance in childhood AML. In this trial, Leukemia doses of etoposide and mitoxantrone were empirically adjusted downward between experimental and control arms to achieve a comparable cytotoxin concentration over time, and equivalent toxicities in both arms. We expected that this dose modification was necessary to mitigate the effects of dose intensity to find whether the blockade of P-gp by CsA increases survival in childhood AML.
Empiric dose reductions based on the effect of modulators on clearance might not always provide similar drug exposure. Our AUC data suggest a wide variation in systemic and presumably tumor exposure to the chemotherapeutic agents. One approach to reduce this variability would be through adaptive control dosing strategies, in which drug concentrations are determined during or after drug administration, and subsequent doses adjusted to achieve a target concentration or drug exposure. That strategy has been effectively used for many regimens including etoposide, 47 topotecan, 48 and antimetabolites. 49 Unfortunately, generalized application of these approaches is limited by necessity for specialized personnel to perform drug quantitation and pharmacokinetic modeling.
Many questions on the role of MDR chemosensitizers and their possible benefits in children with AML remain to be explored. Further studies of MDR modulation and PK studies with incorporation of pharmacogenomic studies might elucidate the combined genetic basis for the relationship of drug concentration, drug metabolism, and tumor response in children. In addition, cyclosporins may have a role beyond P-gp inhibition in the therapy of leukemia. CsA has shown effects on apoptototic and ceramide pathways in in vitro leukemia models.
